Paper Details

  1. Home
  2. Paper Details

Relationship between serum HCV markers and response to interferon therapy in chronic hepatitis C. Evaluation of HCV genotypes during and after long-term follow-up.

Author: BonettiP, CasarinC, DiodatiG, FasolaM, NoventaF, RealdiG, RiberoM, RuolA, TaggerA

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study examined the effect of interferon therapy on hepatitis C virus (HCV) antibodies and viral RNA in 18 patients with chronic hepatitis C. Only patients who responded positively to interferon therapy showed a significant decrease in anti-HCV antibodies, with all becoming negative at the end of follow-up. This decrease specifically affected anti-c100 antibodies, while anti-c22 and anti-c33 remained unchanged. HCV RNA levels mirrored the behavior of anti-HCV, suggesting a close link between anti-c100 disappearance and HCV RNA clearance. The study also found that patients with genotype 2 HCV were more likely to clear the virus during treatment and maintain a negative status compared to those with genotype 1b.
Paper Details　
Original Abstract of the Article :
Hepatitis C virus is the most frequent cause of chronic non-A, non-B hepatitis, and the antibodies to structural and nonstructural proteins encoded by viral genome have been suggested to be markers of ongoing HCV infection. We studied the behavior of these antibodies during interferon therapy in 18 ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/BF02087672

データ提供：米国国立医学図書館（NLM）

Hepatitis C: Examining the Relationship Between Serum Markers and Response to Interferon Therapy

Hepatitis C, a chronic liver infection, can be a challenging foe. This study explores the relationship between serum HCV markers and response to interferon therapy in patients with chronic hepatitis C. The researchers investigated the behavior of antibodies to structural and nonstructural HCV proteins during treatment and during long-term follow-up, seeking to identify potential markers of treatment response.

Anti-HCV Titers as Potential Markers of Treatment Response

The study revealed that a significant decrease in anti-HCV titer was observed only in patients who showed a positive response to interferon therapy. Furthermore, all patients who achieved a sustained virological response were anti-HCV negative at the end of follow-up. These findings suggest that anti-HCV titers, particularly anti-c100, may serve as potential markers of treatment response and sustained viral clearance.

The Role of Genotype in Treatment Response and Long-Term Outcomes

The study also highlights the importance of HCV genotype in treatment response. Patients with genotype 2 showed a higher rate of sustained viral clearance compared to those with genotype 1b. This observation underscores the need to consider HCV genotype when planning treatment strategies and predicting long-term outcomes.

Dr.Camel's Conclusion

The desert of hepatitis C research is vast, with many mysteries to unravel. This study sheds light on the potential value of serum HCV markers in predicting treatment response. The research also underscores the importance of genotype in determining treatment outcomes, emphasizing the need for individualized treatment approaches.

Date :
  1. Date Completed 1994-12-13
  2. Date Revised 2019-07-21
Further Info :

Pubmed ID

7525169

DOI: Digital Object Identifier

10.1007/BF02087672

Related Literature

Article Analysis
・Effective treatment of hepatitis c
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.